Kindred Biosciences, Inc. (KIN) financial statements (2021 and earlier)

Company profile

Business Address 1555 BAYSHORE HIGHWAY, SUITE 200
BURLINGAME, CA 94010
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:60677855748880
Cash and cash equivalents12172714163932
Short-term investments47464039564848
Other undisclosed cash, cash equivalents, and short-term investments2510120 
Receivables1100111
Inventory, net of allowances, customer advances and progress billings0001444
Inventory0001444
Other undisclosed current assets2(0)(5)3112
Total current assets:63687358799487
Noncurrent Assets
Operating lease, right-of-use asset3433322
Property, plant and equipment28293030303029
Long-term investments and receivables2510120 
Long-term investments2510120 
Other noncurrent assets0000000
Total noncurrent assets:33374334353130
TOTAL ASSETS:9610511693114125117
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities556101097
Accounts payable0013111
Accrued liabilities3223454
Employee-related liabilities2244433
Debt1  1111
Other undisclosed current liabilities111    
Total current liabilities:7571010108
Noncurrent Liabilities
Long-term debt and lease obligation2123222222201
Long-term debt, excluding current maturities192019191919 
Operating lease, liability3333311
Other undisclosed noncurrent liabilities(3)(3)(3)    
Total noncurrent liabilities:1923222222201
Total liabilities:2828293232309
Stockholders' equity
Stockholders' equity attributable to parent677787618295108
Common stock0000000
Additional paid in capital312310309306305303300
Accumulated other comprehensive income0000000
Accumulated deficit(245)(234)(222)(246)(223)(207)(192)
Total stockholders' equity:677787618295108
TOTAL LIABILITIES AND EQUITY:9610511693114125117

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Revenues11401111
Cost of revenue
(Cost of Goods and Services Sold)
(0)(0)(0)(4)(0)(0)(0)
Gross profit:1139(3)111
Operating expenses(11)(12)(15)(19)(17)(17)(16)
Other undisclosed operating income (loss)   0(0)00
Operating income (loss):(10)(12)24(22)(15)(16)(15)
Nonoperating income (expense)(1)(1)(0)(0)(0)00
Investment income, nonoperating(0)  0(0)00
Net income (loss) available to common stockholders, diluted:(11)(12)24(23)(16)(15)(14)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net income (loss):(11)(12)24(23)(16)(15)(14)
Comprehensive income (loss):(11)(12)24(23)(16)(15)(14)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)(0)0(0)(0)00
Comprehensive income (loss), net of tax, attributable to parent:(11)(12)24(23)(16)(15)(14)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: